A Phase III, Randomized, Open-Label, Multi-center Study of SHR-1210(Anti-PD-1 Antibody) in Combination With Pemetrexed and Carboplatin as First Line Therapy in Subjects With Advanced/Metastatic Non-squamous Non-small Cell Lung Cancer
Phase of Trial: Phase III
Latest Information Update: 02 Jun 2017
At a glance
- Drugs INCSHR 1210 (Primary) ; Carboplatin; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Jiangsu Hengrui Medicine Co.
- 25 May 2017 Status changed from not yet recruiting to recruiting.
- 03 May 2017 New trial record